Document is current
Any future updates will be listed below
-
Authors
Lim, Amos A.
Pouyabahar, Delaram
Ashraf, Mishal
Huang, Kate https://orcid.org/0000-0002-6515-5324
Lohbihler, Michelle
Murareanu, Brandon M.
Chang, Matthew L.
Kwan, Maggie
Alibhai, Faisal J.
Tran, Thinh
Mazine, Amine
Laflamme, Michael A.
Bader, Gary D. https://orcid.org/0000-0003-0185-8861
Laksman, Zachary https://orcid.org/0000-0002-7790-541X
Protze, Stephanie https://orcid.org/0000-0002-7993-3780
-
Funding
Funding for this research was provided by:
Gouvernement du Canada | Canadian Institutes of Health Research (CIHR PJT 169090, Doctoral Fellowship, Doctoral Fellowship, Postdoctoral Fellowship)
Canadian Stem Cell Network (IRP-ECI-19, Protze), Canadian Foundation for Innovation
Ontario Graduate Scholarship
- License Information
-
More Information
Article History
Received: 4 July 2023
Accepted: 8 November 2024
First Online: 27 November 2024
Competing interests
: S.P. is a paid consultant for BlueRock Therapeutics LP. M.A.L. is a scientific founder and paid consultant for BlueRock Therapeutics LP. G.D.B. is a paid advisor of Adela, Inc.. A.A.L., M.L., and S.P. declare a patent titled “Use of CD34 as a marker for sinoatrial node-like pacemaker cells” (PCT/IB2021/053646) related to this study. All other authors declare no competing interests.
